NOS3 and Cirrhosis: (Verbeke et al., 2014) found that the FXR agonist obeticholic acid reduced portal pressure in a rat model of cirrhosis by decreasing intrahepatic vascular resistance through increased endothelial nitric oxide synthase (eNOS) activity in the liver.